Powered by Business Wire

Kalytera Retains Colwell Capital to Provide Investor Relations Services

SAN FRANCISCO & TEL AVIV, Israel--(BUSINESS WIRE)--Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that it has retained Colwell Capital ("Colwell") to provide investor relations services. The services to be provided by Colwell will include introducing the Company to the Canadian investment community; updating the Company’s investor base on a regular basis; organizing investor road shows for the Company's management; and assisting with the preparation of corporate communications and presentations.

Colwell is a Calgary-based investor relations firm that has represented public and private clients in the biotechnology, technology, resource and industrial sectors for 19 years. Colwell focuses on introducing high quality investment opportunities, such as Kalytera, to its Canadian retail, institutional, analyst and media networks.

BND Projects Inc. will assist Colwell. BND is a Canadian consulting firm founded by Christina Cameron, an acknowledged life sciences capital markets expert with many years of experience in investor relations and investment banking. BND will act at arm's length to the Company, and BND and its principals expect to purchase Kalytera's securities for investment purposes from time to time.

The agreement with Colwell, which is subject to the approval of the TSX Venture Exchange, has an initial term of six months and can be terminated by either party thereafter on 30 days written notice. Colwell will receive a fee of $7,500 per month, and has been granted 60,000 stock options for purchase of the Company's common shares. Kalytera has also granted 60,000 stock options to BND Projects Inc. Such options will have an exercise price of CDN $0.265 per share, being equal to the closing price of the Company's common shares on the TSX Venture Exchange on the trading day prior to the date of grant and will vest in equal quarterly installments over a period of 12 months. The options are being granted pursuant to the terms of the company's stock option plan and are subject to regulatory approval.

About Kalytera Therapeutics

Kalytera Therapeutics, Inc. ("Kalytera") is pioneering the development of a next generation of cannabinoid therapeutics. Through its proven leadership, drug development expertise, and intellectual property portfolio, Kalytera seeks to establish a leading position in the development of novel cannabinoid medicines for a range of important unmet medical needs, with an initial focus on GVHD and treatment of acute and chronic pain.

Cautionary Statements

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This press release may contain certain forward-looking information and statements ("forward-looking information") within the meaning of applicable Canadian securities legislation, that are not based on historical fact, including without limitation in respect of its product candidate pipeline, planned clinical trials, regulatory approval prospects, intellectual property objectives and other statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements depending on, among other things, the risk that future clinical studies may not proceed as expected or may produce unfavourable. Kalytera undertakes no obligation to comment on analyses, expectations or statements made by third parties, its securities, or financial or operating results (as applicable). Although Kalytera believes that the expectations reflected in forward-looking information in this press release are reasonable, such forward-looking information has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Kalytera's control. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and is made as of the date hereof. Kalytera disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

Contacts

Kalytera Therapeutics, Inc.
Robert Farrell, 888-861-2008
President, CEO
info@kalytera.co